- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05167864
Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area (JBDX)
July 18, 2023 updated by: University of Pennsylvania
A Randomized Prospective Evaluation of Four Injectable Neuromodulators in the Glabella Area
The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation.
Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months.
All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions.
Imaging will be repeated post injection to determine change over time.
Study Overview
Status
Completed
Conditions
Detailed Description
This study is a randomized controlled trial in which patients will be randomly assigned into one of four groups: those receiving onabotulinumtoxinA (Botox, Allergan, Irvine, California), abobotulinumtoxinA (Dysport, Ispen Biopharmacueticals Inc.Cambridge, MA), incobotulinumtoxinA (Xeomin, Raleigh, NC) or prabotulinumtoxinA (Jeuveau, Evolus, Newport Beach, California).
Each patient will receive FDA approved dosages in which they are assigned in to treat rhytids within the glabella, as per FDA approved indications.
All injections will be performed by a blinded single trained physician according to a preset injection plan per FDA approved administration guidelines.
Prior to injection patients will be imaged with 3-dimensional photogrammetry.
All pre-procedure images will be evaluated for absolute strain performing two types of facial animation: 1) relaxed, and 2) frowning.
Subjects will return Day 3, 30, 90, and 180, post intervention for re-imaging with the same expressions.
Strain will be calculated using the same metrics.
Study Type
Interventional
Enrollment (Actual)
143
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Robyn Broach, PhD
- Phone Number: 215-662-7300
- Email: robyn.broach@pennmedicine.upenn.edu
Study Contact Backup
- Name: Ivona Percec, MD, PhD
- Phone Number: 215-662-7300
- Email: ivona.percec@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Penn Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Female
- 30-65 years of age
- Interested in glabellar injections to reduce rhytids and facial strain
- Participants must sign the informed consent form
Exclusion Criteria:
- Females under 30 or above 65 years of age
- Males
- Those who have received glabellar injections for rhytids <12 months
- Underwent cosmetic surgical procedure above the malar region
- Those with a condition that affects facial expression, such as prior stroke
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: OnabotulinumtoxinA
Botox
|
cosmetic injection into the glabella area (eyebrow area)
Other Names:
|
Active Comparator: AbobotulinumtoxinA
Dysport
|
cosmetic injection into the glabella area (eyebrow area)
Other Names:
|
Active Comparator: IncobotulinumtoxinA
Xeomin
|
cosmetic injection into the glabella area (eyebrow area)
Other Names:
|
Active Comparator: PrabotulinumtoxinA
Jeuveau
|
cosmetic injection into the glabella area (eyebrow area)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change in dynamic strain in the glabella area after injection over time
Time Frame: baseline, day 3, day 30, day 90, day 180
|
the change in dynamic strain of the glabella area after injection using 3D facial imaging measurements over time
|
baseline, day 3, day 30, day 90, day 180
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change in dynamic strain in the glabella area after injections over time between two facial animations
Time Frame: baseline, day 3, day 30, day 90, day 180
|
the degree of stretch, lift (dynamic strain) of two facial animations (relaxed and frowning)
|
baseline, day 3, day 30, day 90, day 180
|
assess patient reported satisfaction (FACE-Q) to the degree of dynamic strain overtime
Time Frame: baseline, day 3, day 30, day 90, day 180
|
assess patient reported satisfaction (FACE-Q) to the degree of dynamic strain overtime.
All modules of the FACE-Q create a total score converted to 0 to 100.
Higher scores for all modules except 2 ("Expectations" and "Appearance-related Distress") reflect a better outcome.
|
baseline, day 3, day 30, day 90, day 180
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 4, 2022
Primary Completion (Actual)
June 30, 2023
Study Completion (Actual)
June 30, 2023
Study Registration Dates
First Submitted
December 3, 2021
First Submitted That Met QC Criteria
December 16, 2021
First Posted (Actual)
December 22, 2021
Study Record Updates
Last Update Posted (Actual)
July 19, 2023
Last Update Submitted That Met QC Criteria
July 18, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins, Type A
- abobotulinumtoxinA
- incobotulinumtoxinA
Other Study ID Numbers
- 849045
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cosmetic Techniques
-
University of MalayaCompletedMammaplasty | Cosmetic TechniquesMalaysia
-
University of PennsylvaniaGalderma R&DActive, not recruiting
-
Christie Medical Holdings, Inc.Completed
-
CIBA VISIONCompletedCosmetic Appearance
-
National Taiwan University HospitalUnknownReproductive Techniques, Assisted | Investigative Techniques | Reproductive TechniquesTaiwan
-
Ungku Shahrin Medical Aesthetic Research & Innovation...CompletedHealthy | Aesthetic | CosmeticMalaysia
-
Johnson & Johnson Vision Care, Inc.Completed
-
Seoul National University HospitalUnknown
-
CIBA VISIONCompletedCosmetic AppearanceSingapore
-
Cynosure, Inc.CompletedUnwanted, Non Cosmetic, TattoosUnited States
Clinical Trials on Onabotulinumtoxina for Injection
-
Bio-Thera SolutionsNot yet recruiting
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
AstraZenecaCompletedHealthy Elderly | Mild-Moderate Alzheimer's DiseaseUnited States
-
Shanghai Junshi Bioscience Co., Ltd.RecruitingLimited-stage Small Cell Lung Cancer (LS-SCLC)China, Taiwan, Georgia, United States
-
AstraZenecaCompletedChronic PainGermany, Sweden, United Kingdom
-
Aro BiotherapeuticsRecruiting
-
Dartmouth-Hitchcock Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at Birmingham and other collaboratorsRecruitingOveractive Bladder | Urinary Incontinence in Old Age | Urgency Urinary IncontinenceUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingMetastatic Castration-resistant Prostate Cancer (mCRPC)China